TVTX 21.11 ▲ 7.65% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Travere Therapeutics Inc.

    NASDAQ: TVTX · Real-Time Price · USD
    21.11
    1.50 (7.65%)
    At close: Sep 04, 2025, 3:50 PM
    7.65%
    Bid 21.08
    Market Cap 1.88B
    Revenue (ttm) 333.87M
    Net Income (ttm) -169.06M
    EPS (ttm) -2.02
    PE Ratio (ttm) -10.45
    Forward PE 35.59
    Analyst Buy
    Ask 21.14
    Volume 2,732,700
    Avg. Volume (20D) 1,731,074.2
    Open 19.71
    Previous Close 19.61
    Day's Range 19.46 - 21.12
    52-Week Range 9.44 - 25.29
    Beta 0.75

    About TVTX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TVTX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for TVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Travere Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +1.49%
    Travere Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
    3 months ago
    -20.57%
    Travere Therapeutics shares are trading lower. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.
    news image

    1 day ago · businesswire.com

    Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

    SAN DIEGO--(BUSINESS WIRE)---- $TVTX #ICIEM2025--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the Inte...

    news image

    2 days ago · seekingalpha.com

    Travere Therapeutics, Inc. (TVTX) Presents At Citi's Biopharma Back To School Conference Transcript

    Travere Therapeutics, Inc. (NASDAQ:TVTX ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Eric Dube - President, CEO & Director Peter Heerma - Chief Comme...

    news image

    6 days ago · benzinga.com

    FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

    The U.S. Food and Drug Administration (FDA) on Wednesday approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Travere Therapeutics, Inc.'s TVTX Filspari (sparsentan), the only ...

    news image

    1 week ago · businesswire.com

    Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

    SAN DIEGO--(BUSINESS WIRE)---- $TVTX #IgAN--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigat...

    news image

    3 weeks ago · seekingalpha.com

    Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

    Travere Therapeutics has successfully executed a significant restructuring to recover from previous setbacks and improve its financial health. It has built a compact pipeline of kidney therapy drugs w...

    news image

    3 weeks ago · businesswire.com

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to ...

    news image

    4 weeks ago · seekingalpha.com

    Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

    Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Di...

    news image

    4 weeks ago · zacks.com

    Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

    Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street e...

    news image

    4 weeks ago · zacks.com

    Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

    Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.

    news image

    4 weeks ago · businesswire.com

    Travere Therapeutics Reports Second Quarter 2025 Financial Results

    SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. “We continue to make strong progress ag...

    Add to Watchlist